SW40/41 Tubes with short caps
- Known as:
- SW40/41 Tubes short caps
- Catalog number:
- 1054146
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Accurate
- Gene target:
- SW40/41 Tubes with short caps
Related genes to: SW40/41 Tubes with short caps
- Gene:
- CAPS NIH gene
- Name:
- calcyphosine
- Previous symbol:
- -
- Synonyms:
- CAPS1, MGC126562
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-05-31
- Date modifiied:
- 2016-07-18
Related products to: SW40/41 Tubes with short caps
Related articles to: SW40/41 Tubes with short caps
- How dendrites of different neurons segregate into discrete spatial domains during neural circuit assembly is poorly understood. Here, using the Drosophila olfactory system, we found that heterophilic interactions between two cell-surface proteins, Teneurin-m (Ten-m) and Capricious (Caps), drive dendrite segregation. Ten-m and Caps are expressed in largely inverse patterns across projection neuron (PN) types when PNs are establishing their dendritic territories. Loss of Ten-m in Ten-m PNs causes their dendrites to invade Caps territories, whereas loss of Caps in Caps PNs causes dendrite invasion into Ten-m territories. Structure-guided mutations that abolish Ten-m-Caps binding disrupt dendrite segregation, whereas the same mutation on Ten-m preserves its homophilic attraction in a synaptic partner matching assay. These results support a model in which mutual repulsions between two inversely expressed cell-surface proteins drive dendrite segregation into discrete glomerular territories. - Source: PubMed
Publication date: 2026/09/21
Ji HuiLi JingxianXu YizhenWong Kenneth Kin LamWu YunmingLuginbuhl David JZhang YanboLi ZhuoranLee JaeyoonJones Robert CQuake Stephen RAraç DemetÖzkan EnginLuo Liqun - To characterize peripheral macrovascular thrombosis in patients with catastrophic antiphospholipid syndrome (CAPS) and to analyse clinical and laboratory differences between episodes with and without peripheral macrovascular thrombosis, and between arterial and venous events. - Source: PubMed
Publication date: 2026/09/13
Vilaplana BertaRussa AngelinaJerez AlbaPons IsaacPonce AnaToledano PilarRossiñol TomeuRodríguez-Pintó IgnasiErkan DorukEspinosa GerardCervera Ricard - Prolonged Exposure (PE) is a first-line evidence-based treatment for Posttraumatic Stress Disorder (PTSD), with well-established efficacy in randomised controlled trials. However, its implementation in routine care remains limited, particularly in outpatient clinics where evidence-based psychotherapies are not widely adopted. This study aimed to evaluate the feasibility, safety and effectiveness of PE therapy delivered in a real-world outpatient setting. Data were obtained from 95 adults diagnosed with PTSD using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) who received PE in a French outpatient clinic. The sample was characterised by a mean age of 35.65 years (SD = 13.16), 76% women ( = 72), a mean CAPS-5 score of 38 (SD = 9.4), and 61% reporting sexual trauma as the index event. PTSD Checklist for DSM-5 (PCL-5) and Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-16-SR) were assessed at intake, pre-treatment, post-treatment and three-month follow-up. Mean changes were estimated using a linear mixed-effects model. Patients received an average of 8 sessions of PE (SD = 3.75). Scores consistent with probable remission (PCL-5 < 33) was observed in 75.53% of patients, and 79.78% demonstrated a clinically significant improvement (≥10-point reduction on the PCL-5). A large decrease in PTSD symptoms was observed from pre- to post-treatment (Δ = 25.57, = 1.88, < .001), and to 3-month follow-up ( = 2.17, < .001), exceeding the small effect found during the waiting-list phase ( = 0.33, = .01). Similar improvements were found for depressive symptoms. Only 1% of patients showed a reliable clinical symptom worsening (≥10-points increase on the PCL-5) and the dropout rate was 9.47% (fewer than eight sessions completed without remission). These findings suggest that PE may be feasibly and safely delivered in routine outpatient care and may be associated with substantial reductions in PTSD symptoms. They highlight the potential for successful Implementation of evidence-based trauma treatments in real-world clinical settings where structured psychotherapies are not yet widely integrated. - Source: PubMed
Publication date: 2026/09/21
Rascol ThéoGosselin Pierre-AndréAvrillon DelphineBrodin LaurentChauvel HélèneDujardin NoémieLopes Bruna GomesLaplante NathaliePonty CélineSagols QuentinCousin AnnabelleKheng EmmaGuillery BérengèreCharretier LauraBui Eric - Uncovering the identity of "dark fungi" is crucial for understanding fungal taxonomy, diversity, and phylogenetic relationships. Previous exploratory analysis of the mycorrhizal fungi of the partially mycoheterotrophic orchid revealed an association with a particular group of , tentatively designated "unidentified X" (uAX). Two culture strains were successfully isolated from the mycorrhiza, which enabled the phylogenetic position of this fungus to be determined using ultrastructural and multigene phylogenetic analyses. Transmission electron microscopy observations of the two cultures of uAX revealed that the dolipore septum is associated with perforate septal pore caps (SPCs), the margins of which are reflexed outwards. This combination of characters has not previously been reported in any order of . Combined phylogenetic analyses based on sequence data from four loci [5.8S and 28S ribosomal DNA (rDNA), translation elongation factor 1-α, and RNA polymerase II second large subunit] indicate that uAX is an early-diverging clade of that cannot be accommodated in any known order of . The name is proposed here for this new order of . Furthermore, BLAST searches of the internal transcribed spacers of nuclear ribosomal DNA (nrDNA) and phylogenetic analyses reveal that closely related taxa have previously been detected in soil, leaf litter, and living root samples collected at various locations worldwide. This suggests that the group is ubiquitously distributed and probably exhibits a saprotrophic lifestyle. - Source: PubMed
Publication date: 2026/09/11
Kinoshita AkihikoFujimori ShoheiSeto KensukeOgura-Tsujita YukiMaeda AyakoGale Stephan WAbe Junichi PDegawa YousukeYukawa Tomohisa - Japan has one of the world's lowest fertility rates, and assisted reproductive technology (ART) now accounts for a substantial and growing share of Japanese births. In early 2022, general infertility treatment, ART, and male infertility treatment were incorporated into Japan's universal health insurance, replacing a means-tested subsidy and largely self-funded model with insured care at a fixed coinsurance rate. The insured pathway is bounded by an upper age limit for initiating treatment, caps on the number of covered embryo transfers that tighten with age, and the prohibition on mixed billing except for designated advanced medical care. This narrative review examines the early clinical implications of the reform for practicing obstetrician-gynecologists by describing national ART outcomes before and after coverage using the Japan Society of Obstetrics and Gynecology (JSOG) registry and placing Japanese practice in an international context. Relevant literature and registry data were identified by searching PubMed and Google Scholar together with the primary Japanese registry and policy sources and the major international ART registries. In the two years after coverage began, registered cycles and ART-derived neonates rose to successive record highs, and access broadened particularly among younger patients, while Japan's characteristic profile of minimal stimulation, freeze-all with frozen-thawed embryo transfer, and predominant single embryo transfer (SET) was largely maintained. However, the overall SET rate declined, and multiple pregnancies increased in the first full insured year, particularly among older patients; these findings are consistent with, but do not prove, a possible incentive effect of fixed transfer caps. Internationally, conventional fresh-cycle live-birth metrics are difficult to interpret for Japan because of its practice pattern and older patient population, whereas its multiple-birth rate remains among the world's lowest. For clinicians, the priorities of the insured era are to raise the age-43 timeline early, defend elective SET near coverage limits, and make explicit the mixed-billing trade-offs of non-covered options such as preimplantation genetic testing (PGT). - Source: PubMed
Publication date: 2026/08/20
Inoue Daichi